252 related articles for article (PubMed ID: 1698787)
1. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
[TBL] [Abstract][Full Text] [Related]
2. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
[TBL] [Abstract][Full Text] [Related]
3. Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin.
Owensby DA; Morton PA; Wun TC; Schwartz AL
J Biol Chem; 1991 Mar; 266(7):4334-40. PubMed ID: 1705551
[TBL] [Abstract][Full Text] [Related]
4. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor.
Seiffert D; Wagner NN; Loskutoff DJ
J Cell Biol; 1990 Sep; 111(3):1283-91. PubMed ID: 1697297
[TBL] [Abstract][Full Text] [Related]
5. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
Seiffert D; Mimuro J; Schleef RR; Loskutoff DJ
Cell Differ Dev; 1990 Dec; 32(3):287-92. PubMed ID: 1711915
[TBL] [Abstract][Full Text] [Related]
6. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin.
Seiffert D; Loskutoff DJ
J Biol Chem; 1991 Feb; 266(5):2824-30. PubMed ID: 1704366
[TBL] [Abstract][Full Text] [Related]
7. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
8. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells.
Mimuro J; Loskutoff DJ
J Biol Chem; 1989 Mar; 264(9):5058-63. PubMed ID: 2494180
[TBL] [Abstract][Full Text] [Related]
9. Reactivity of synthetic peptide analogs of adhesive proteins in regard to the interaction of human endothelial cells with extracellular matrix.
Chen CS; Hawiger J
Blood; 1991 May; 77(10):2200-6. PubMed ID: 1709375
[TBL] [Abstract][Full Text] [Related]
10. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.
Ramakrishnan V; Sinicropi DV; Dere R; Darbonne WC; Bechtol KB; Baker JB
J Biol Chem; 1990 Feb; 265(5):2755-62. PubMed ID: 2105933
[TBL] [Abstract][Full Text] [Related]
11. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.
Seiffert D; Ciambrone G; Wagner NV; Binder BR; Loskutoff DJ
J Biol Chem; 1994 Jan; 269(4):2659-66. PubMed ID: 7507927
[TBL] [Abstract][Full Text] [Related]
12. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
Ehrlich HJ; Keijer J; Preissner KT; Gebbink RK; Pannekoek H
Biochemistry; 1991 Jan; 30(4):1021-8. PubMed ID: 1703436
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon.
Niedbala MJ; Picarella MS
Blood; 1992 Feb; 79(3):678-87. PubMed ID: 1732009
[TBL] [Abstract][Full Text] [Related]
14. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
Ehrlich HJ; Gebbink RK; Preissner KT; Keijer J; Esmon NL; Mertens K; Pannekoek H
J Cell Biol; 1991 Dec; 115(6):1773-81. PubMed ID: 1721912
[TBL] [Abstract][Full Text] [Related]
15. Binding of tissue-type plasminogen activator with human endothelial cell monolayers. Characterization of the high affinity interaction with plasminogen activator inhibitor-1.
Russell ME; Quertermous T; Declerck PJ; Collen D; Haber E; Homcy CJ
J Biol Chem; 1990 Feb; 265(5):2569-75. PubMed ID: 2105930
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin.
Seiffert D; Loskutoff DJ
Biochim Biophys Acta; 1991 May; 1078(1):23-30. PubMed ID: 1710930
[TBL] [Abstract][Full Text] [Related]
17. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator.
Hekman CM; Loskutoff DJ
Arch Biochem Biophys; 1988 Apr; 262(1):199-210. PubMed ID: 3128176
[TBL] [Abstract][Full Text] [Related]
18. Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin.
de Boer HC; Preissner KT; Bouma BN; de Groot PG
J Biol Chem; 1992 Feb; 267(4):2264-8. PubMed ID: 1370815
[TBL] [Abstract][Full Text] [Related]
19. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
[TBL] [Abstract][Full Text] [Related]
20. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin.
Mimuro J; Muramatsu S; Kurano Y; Uchida Y; Ikadai H; Watanabe S; Sakata Y
Biochemistry; 1993 Mar; 32(9):2314-20. PubMed ID: 7680229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
